invega- paliperidone tablet, extended release
tya pharmaceuticals - paliperidone (unii: 838f01t721) (paliperidone - unii:838f01t721) - paliperidone 3 mg - invega (paliperidone) extended-release tablets are indicated for the treatment of schizophrenia . ® [see ] clinical studies (14.1) the efficacy of invega in schizophrenia was established in three 6-week trials in adults and one 6-week trial in adolescents, as well as one maintenance trial in adults. ® invega (paliperidone) extended-release tablets are indicated for the treatment of schizoaffective disorder as monotherapy and an adjunct to mood stabilizers and/or antidepressant therapy . ® [see ] clinical studies (14.2) the efficacy of invega in schizoaffective disorder was established in two 6-week trials in adults. ® hypersensitivity reactions, including anaphylactic reactions and angioedema, have been observed in patients treated with risperidone and paliperidone. invega (paliperidone) i
invega- paliperidone tablet, extended release
janssen pharmaceuticals, inc. - paliperidone (unii: 838f01t721) (paliperidone - unii:838f01t721) - paliperidone 3 mg - invega ® (paliperidone) extended-release tablets are indicated for the treatment of schizophrenia [see clinical studies (14.1)] . the efficacy of invega ® in schizophrenia was established in three 6-week trials in adults and one 6-week trial in adolescents, as well as one maintenance trial in adults. invega ® (paliperidone) extended-release tablets are indicated for the treatment of schizoaffective disorder as monotherapy and an adjunct to mood stabilizers and/or antidepressant therapy [see clinical studies (14.2)] . the efficacy of invega ® in schizoaffective disorder was established in two 6-week trials in adults. invega ® is contraindicated in patients with a known hypersensitivity to either paliperidone or risperidone, or to any of the excipients in the invega ® formulation. hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported in patients treated with risperidone and in patients treated with paliperidone. pali
paliperidone teva 50 mg inj. susp. prol.-rel. i.m. pre-filled syr.
teva pharma belgium sa-nv - paliperidone palmitate 156 mg/ml - eq. paliperidone 100 mg/ml - prolonged-release suspension for injection - 50 mg - paliperidone palmitate 156 mg/ml - paliperidone
paliperidone teva 25 mg inj. susp. prol.-rel. i.m. pre-filled syr.
teva pharma belgium sa-nv - paliperidone palmitate 156 mg/ml - eq. paliperidone 100 mg/ml - prolonged-release suspension for injection - 25 mg - paliperidone palmitate 156 mg/ml - paliperidone
paliperidone teva 75 mg inj. susp. prol.-rel. i.m. pre-filled syr.
teva pharma belgium sa-nv - paliperidone palmitate 156 mg/ml - eq. paliperidone 100 mg/ml - prolonged-release suspension for injection - 75 mg - paliperidone palmitate 156 mg/ml - paliperidone
paliperidone teva 100 mg inj. susp. prol.-rel. i.m. pre-filled syr.
teva pharma belgium sa-nv - paliperidone palmitate 156 mg/ml - eq. paliperidone 100 mg/ml - prolonged-release suspension for injection - 100 mg - paliperidone palmitate 156 mg/ml - paliperidone
paliperidone teva 150 mg inj. susp. prol.-rel. i.m. pre-filled syr.
teva pharma belgium sa-nv - paliperidone palmitate 156 mg/ml - eq. paliperidone 100 mg/ml - prolonged-release suspension for injection - 150 mg - paliperidone palmitate 156 mg/ml - paliperidone
invega 3 mg
j-c health care ltd - paliperidone - tablets extended release - paliperidone 3 mg - paliperidone - paliperidone - invega is indicated for :-treatment of schizophrenia in adults and adolescents (12-17 years).-treatment of schizoaffective disorder in adults.
invega 6 mg
j-c health care ltd - paliperidone - tablets extended release - paliperidone 6 mg - paliperidone - paliperidone - invega is indicated for :-treatment of schizophrenia in adults and adolescents (12-17 years).-treatment of schizoaffective disorder in adults.
invega 9 mg
j-c health care ltd - paliperidone - tablets extended release - paliperidone 9 mg - paliperidone - paliperidone - invega is indicated for :-treatment of schizophrenia in adults and adolescents (12-17 years).-treatment of schizoaffective disorder in adults.